Abstract: 1031763 research-article2021 IJI0010.1177/20587384211031763International Journal of Immunopathology and PharmacologyGolpour et al. Letter to the Editor The effectiveness of Colchicine as an anti-inflammatory drug in the treatment of coronavirus disease 2019: Meta-analysis International Journal of Immunopathology and Pharmacology Volume 35: 1–8 © The Author(s) 2021 Article reuse guidelines: sagepub.com/journals-permissions https://doi.org/10.1177/20587384211031763 DOI: 10.1177/20587384211031763 journals.sagepub.com/home/iji Monireh Golpour1 , Tahoora Mousavi2, Mina Alimohammadi3, Ali Mosayebian3, Mohammadreza Shiran4, Reza Alizadeh Navaei5 and Alireza Rafiei3 Abstract A recently discovered coronavirus, SARS-CoV-2, caused a global respiratory disease pandemic called COVID-19. Many studies have shown the excessive activation of the innate immune response that leads to the adverse outcomes of COVID-19, and anti-inflammatory drugs are very useful in the treatment and management of this infection. The activities of Colchicine, one of the anti-inflammatory drugs, target several pathways related to excessive inflammation of COVID-19. This study aimed to evaluate the efficacy of Colchicine in the treatment of COVID-19 using a meta-analysis approach. Scopus, Pubmed, Google scholars, Web of Science, and Science direct were used to search all the randomized controlled trials, case-control, and cross-sectional studies that have evaluated the efficacy of Colchicine as a treatment for COVID-19 (up to 28 May 2021). The overall effect of Colchicine versus the control group was determined using a random-effects model meta-analysis where we compared changes (i.e. mean differences—Colchicine group vs Control group) between the two conditions in test scores indicative of hospitalization time (day) and mortality rate. The results illustrated Colchicine therapy is associated with a decreased mortality rate in COVID-19 patients and associated with a decrease in hospitalization time (day) in COVID-19 patients. Present preliminary data shows that Colchicine has a beneficial effect on coronavirus disease care in 2019. Therefore, Colchicine can be a good suggestion in the management of COVID-19. Keywords Colchicine, COVID-19, hospitalization time, mortality rate, anti-inflammatory Date received: 4 February 2021; accepted: 16 June 2021 1  olecular and Cell Biology Research Center, Student Research M Committee, Faculty of Medicine, Mazandaran University of Medical Science, Sari, Iran 2 Molecular and Cell Biology Research Center, Hemoglobinopathy Research Institute, Mazandaran University of Medical Sciences, Sari, Iran 3 Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran 4  epartment of Physiology and Pharmacology, School of Medicine, D Mazandaran University of Medical Sciences, Sari, Iran 5 Gastrointestinal Cancer Research Center, Non-Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran Corresponding author: Alireza Rafiei, Mazandaran University of Medical Sciences, Sari 4816895482, Iran. Email: rafiei1710@gmail.com Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on..